NIKKEI 225
38,356.06 +176.60 (+0.46%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.42 +0.40 (+0.51%) GOLD FUTURES
2,362.20 +2.30 (+0.10%) DOW
39,558.11 +126.60 (+0.32%) Bitcoin GBP
48,996.62 -864.40 (-1.73%)
MRK Sep 2024 155.000 call
| Previous close | 0.2900 |
| Open | 0.2700 |
| Bid | 0.2400 |
| Ask | 0.3200 |
| Strike | 155.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.2700 - 0.2700 |
| Contract range | N/A |
| Volume | |
| Open interest | 80 |
ZacksMerck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
BenzingaMerck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Monday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab) compared to Keytruda alone as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV). Also Read: Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook. Data from a pre-planned analysis showed tha
Business WireMerck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
